Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.
- W. Wierda, T. Kipps, +17 authors A. Osterborg
- Medicine
- Journal of clinical oncology : official journal…
- 1 April 2010
PURPOSE
New treatments are needed for patients with fludarabine- and alemtuzumab-refractory (FA-ref) chronic lymphocytic leukemia (CLL) or patients with fludarabine-refractory CLL with bulky (> 5 cm)… Expand
Autologous stem cell transplantation for progressive multiple sclerosis: Update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database
- R. Saccardi, T. Kozák, +38 authors G. Mancardi
- Medicine
- Multiple sclerosis
- 1 November 2006
Over the last decade, hematopoietic stem cells transplantation (HSCT) has been increasingly used in the treatment of severe progressive autoimmune diseases. We report a retrospective survey of 183… Expand
Toll‐like receptors on B‐CLL cells: expression and functional consequences of their stimulation
- D. Rožková, Linda Novotná, +4 authors R. Špíšek
- Medicine
- International journal of cancer
- 1 March 2010
Toll‐like receptor (TLR) stimulation plays a crucial role in the homeostasis of human B cells. We investigated the expression of TLRs 1–9 on the cells of B‐cell chronic lymphocytic leukemia (B‐CLL)… Expand
Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years’ experience from the European Group for Blood and Marrow Transplantation Working Party…
- D. Farge, M. Labopin, +11 authors R. Saccardi
- Medicine
- Haematologica
- 1 February 2010
Background Autologous hematopoietic stem cell transplantation has been used since 1996 for the treatment of severe autoimmune diseases refractory to approved therapies. We evaluated the long-term… Expand
Candidatus Neoehrlichia mikurensis infection identified in 2 hematooncologic patients: benefit of molecular techniques for rare pathogen detection.
- S. Pekova, J. Vydra, +7 authors T. Kozák
- Medicine, Biology
- Diagnostic microbiology and infectious disease
- 1 March 2011
Hematooncologic patients often host rare or fastidious pathogens. Using 16S rDNA sequencing and transmission electron microscopy, we have identified 2 lymphoma patients infected with Candidatus… Expand
Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study.
- A. Fassas, J. Passweg, +28 authors J. Samijn
- Medicine
- Journal of neurology
- 2002
RATIONALE
Phase I/II studies of autologous hematopoietic stem cell transplantation (HSCT) for multiple sclerosis ( MS) were initiated, based on results of experimental transplantation in animal… Expand
Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis
- P. Muraro, M. Pasquini, +25 authors R. Saccardi
- Medicine
- JAMA neurology
- 1 April 2017
Importance Autologous hematopoietic stem cell transplantation (AHSCT) may be effective in aggressive forms of multiple sclerosis (MS) that fail to respond to standard therapies. Objective To evaluate… Expand
Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases.
- J. Snowden, M. Badoglio, +16 authors D. Farge
- Medicine
- Blood advances
- 26 December 2017
Hematopoietic stem cell transplantation (HSCT) has evolved for >20 years as a specific treatment of patients with autoimmune disease (AD). Using European Society for Blood and Marrow Transplantation… Expand
Role of [18F]-fluoro-2-deoxy-d-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin,…
- J. Marková, D. Kahraman, +8 authors T. Kozák
- Medicine
- Leukemia & lymphoma
- 1 January 2012
Abstract The prognostic value of positron emission tomography (PET) in early therapy response assessment, after completion of chemotherapy and 3 months after the end of treatment in advanced Hodgkin… Expand
FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value.
- J. Marková, C. Kobe, +7 authors T. Kozák
- Medicine
- Annals of oncology : official journal of the…
- 1 July 2009
BACKGROUND
As positron emission tomography (PET) seems to be a powerful prognostic marker in the treatment of Hodgkin's lymphoma (HL), we analysed the prognostic value of PET after four cycles of… Expand